Abstract
Background--The majority of hypertensive individuals require combination antihypertensive therapy to achieve adequate blood pressure (BP) control. This study aimed to identify genetic variants associated with uncontrolled BP on combination therapy with a thiazide diuretic and a β-blocker. Methods and Results--A genome-wide association study of uncontrolled BP on combination therapy was conducted among 314 white participants of the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) trial. Multivariable logistic regression analysis was used. Genetic variants meeting a suggestive level of significance (P < 1.0E-05) were tested for replication in an external cohort, INVEST (International Verapamil-SR Trandolapril study). We also examined genome-wide variant associations with systolic and diastolic BP response on combination therapy and tested for replication. We discovered a single nucleotide polymorphism, the rs261316 major allele, at chromosome 15 in the gene ALDH1A2 associated with an increased odds of having uncontrolled BP on combination therapy (odds ratio: 2.56, 95% confidence interval, 1.69-3.88, P=8.64E-06). This single nucleotide polymorphism replicated (odds ratio: 1.86, 95% confidence interval, 1.35-2.57, P=0.001) and approached genome-wide significance in the metaanalysis between discovery and replication cohorts (odds ratio: 2.16, 95% confidence interval, 1.63-2.86, P=8.60E-08). Other genes in the region surrounding rs261316 (ALDH1A2) include AQP9 and LIPC. Conclusions--A single nucleotide polymorphism in the gene ALDH1A2 may be associated with uncontrolled BP following treatment with a thiazide diuretic/β-blocker combination.
| Original language | English |
|---|---|
| Article number | e006522 |
| Journal | Journal of the American Heart Association |
| Volume | 6 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 01-11-2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cardiology and Cardiovascular Medicine
Cite this
}
Genetic variants associated with uncontrolled blood pressure on thiazide diuretic/β-blocker combination therapy in the PEAR (Pharmacogenomic Evaluation Of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) trials. / Magvanjav, Oyunbileg; Gong, Yan; McDonough, Caitrin W.; Chapman, Arlene B.; Turner, Stephen T.; Gums, John G.; Bailey, Kent R.; Boerwinkle, Eric; Beitelshees, Amber L.; Tanaka, Toshihiro; Kubo, Michiaki; Pepine, Carl J.; Cooper-DeHoff, Rhonda M.; Johnson, Julie A.
In: Journal of the American Heart Association, Vol. 6, No. 11, e006522, 01.11.2017.Research output: Contribution to journal › Article
TY - JOUR
T1 - Genetic variants associated with uncontrolled blood pressure on thiazide diuretic/β-blocker combination therapy in the PEAR (Pharmacogenomic Evaluation Of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) trials
AU - Magvanjav, Oyunbileg
AU - Gong, Yan
AU - McDonough, Caitrin W.
AU - Chapman, Arlene B.
AU - Turner, Stephen T.
AU - Gums, John G.
AU - Bailey, Kent R.
AU - Boerwinkle, Eric
AU - Beitelshees, Amber L.
AU - Tanaka, Toshihiro
AU - Kubo, Michiaki
AU - Pepine, Carl J.
AU - Cooper-DeHoff, Rhonda M.
AU - Johnson, Julie A.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Background--The majority of hypertensive individuals require combination antihypertensive therapy to achieve adequate blood pressure (BP) control. This study aimed to identify genetic variants associated with uncontrolled BP on combination therapy with a thiazide diuretic and a β-blocker. Methods and Results--A genome-wide association study of uncontrolled BP on combination therapy was conducted among 314 white participants of the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) trial. Multivariable logistic regression analysis was used. Genetic variants meeting a suggestive level of significance (P < 1.0E-05) were tested for replication in an external cohort, INVEST (International Verapamil-SR Trandolapril study). We also examined genome-wide variant associations with systolic and diastolic BP response on combination therapy and tested for replication. We discovered a single nucleotide polymorphism, the rs261316 major allele, at chromosome 15 in the gene ALDH1A2 associated with an increased odds of having uncontrolled BP on combination therapy (odds ratio: 2.56, 95% confidence interval, 1.69-3.88, P=8.64E-06). This single nucleotide polymorphism replicated (odds ratio: 1.86, 95% confidence interval, 1.35-2.57, P=0.001) and approached genome-wide significance in the metaanalysis between discovery and replication cohorts (odds ratio: 2.16, 95% confidence interval, 1.63-2.86, P=8.60E-08). Other genes in the region surrounding rs261316 (ALDH1A2) include AQP9 and LIPC. Conclusions--A single nucleotide polymorphism in the gene ALDH1A2 may be associated with uncontrolled BP following treatment with a thiazide diuretic/β-blocker combination.
AB - Background--The majority of hypertensive individuals require combination antihypertensive therapy to achieve adequate blood pressure (BP) control. This study aimed to identify genetic variants associated with uncontrolled BP on combination therapy with a thiazide diuretic and a β-blocker. Methods and Results--A genome-wide association study of uncontrolled BP on combination therapy was conducted among 314 white participants of the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) trial. Multivariable logistic regression analysis was used. Genetic variants meeting a suggestive level of significance (P < 1.0E-05) were tested for replication in an external cohort, INVEST (International Verapamil-SR Trandolapril study). We also examined genome-wide variant associations with systolic and diastolic BP response on combination therapy and tested for replication. We discovered a single nucleotide polymorphism, the rs261316 major allele, at chromosome 15 in the gene ALDH1A2 associated with an increased odds of having uncontrolled BP on combination therapy (odds ratio: 2.56, 95% confidence interval, 1.69-3.88, P=8.64E-06). This single nucleotide polymorphism replicated (odds ratio: 1.86, 95% confidence interval, 1.35-2.57, P=0.001) and approached genome-wide significance in the metaanalysis between discovery and replication cohorts (odds ratio: 2.16, 95% confidence interval, 1.63-2.86, P=8.60E-08). Other genes in the region surrounding rs261316 (ALDH1A2) include AQP9 and LIPC. Conclusions--A single nucleotide polymorphism in the gene ALDH1A2 may be associated with uncontrolled BP following treatment with a thiazide diuretic/β-blocker combination.
UR - http://www.scopus.com/inward/record.url?scp=85034776600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034776600&partnerID=8YFLogxK
U2 - 10.1161/JAHA.117.006522
DO - 10.1161/JAHA.117.006522
M3 - Article
C2 - 29097388
AN - SCOPUS:85034776600
VL - 6
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 11
M1 - e006522
ER -